Patent Application
20250152481
The invention relates to a liposomal composition comprising biosurfactants and the use of the liposomal composition for encapsulation of at least one cosmetic, pharmaceutical and/or nutraceutical active ingredient.
U.S. Pat. No. 4,902,512 discloses liposomes formed by 2-O-alpha-decenoyl-alpha-L-rhamnopyranosyl-beta-hydroxydecanoyl-beta-hydroxydecanoic acid and 2-O-(2-O-alpha-decenoyl-alpha-rhamnopyranosyl)-alpha-L-rhamnopyranosyl-beta-hydroxydecanoyl-beta-hydroxydecanoic acid.
US2019021338A1 discloses the application of a peptide inside a rhamnolipid liposome to plants, trees and bushes to kill diseases and plant pathogens affecting those plants, trees and bushes.
CN108158997 discloses the use of rhamnolipids for the preparation of membrane materials targeted to tumor cell liposomes is characterized in that said tumor cells are tumor cells expressing rhamnose receptors.
EP2654779 discloses liposomes comprising: a lipid bilayer membrane surrounding an aqueous core, wherein the lipid bilayer comprises:
CN100536817 discloses ceramide nanoliposome preparations, characterized in that the ceramide nanoliposome preparation contains the following components by weight percentage: ceramide 0.1 to ˜5%, phospholipid 0.1 to ˜20%, glycerol 10 to ˜70% and water 25 to ˜80%, EP1138311 discloses pro-liposomally encapsulated preparations obtainable by treating UV light protection filters and/or antioxidants in cosmetically acceptable solvents with lecithins and/or phospholipids.
It is an object of the invention to provide liposomal compositions which allows solubilization of hardly soluble substances with outstanding long-time stability in terms of re-precipitation.
It was found that, surprisingly, that liposomal compositions comprising phospholipid and biosurfactant solve the problem of the instant invention.
The present invention therefore provides a composition comprising liposomes and biosurfactant as described in more detail in claim 1.
The invention further provides a process for encapsulating at least one cosmetic, pharmaceutical and/or nutraceutical active as described in more detail in claim 11.
One advantage of the present invention is that the compositions according to the instant invention have an outstanding stability.
Another advantage of the present invention is that the compositions according to the instant invention can keep hardly soluble substances in solution.
A further advantage is that precipitation and/or crystallization of for examples actives from liposomes will be prevented.
Another advantage of the present invention is that the bioavailability of actives, especially hardly soluble actives, is enhanced.
Another advantage of the present invention is that the compositions according to the instant invention are easy to formulate into cosmetic, pharmaceutical and nutraceutical applications.
Another advantage of the present invention is that the irritation potential of compounds contained in the compositions according to the instant invention is decreased.
Another advantage of the present invention is that the composition according to the instant invention enables economic and sustainable processing at low temperatures.
Another advantage of the present invention is that the composition according to the instant invention chemically stabilizes actives, for example prevents the degradation of actives.
Another advantage of the present invention is that the composition according to the instant invention enhances compatibility of hardly soluble substances with other formulation ingredients.
Another advantage of the present invention is that the composition according to the instant invention is non-irritant to the skin.
Another advantage of the present invention is that the biosurfactants contained in the composition according to the instant invention stabilize the liposomal structures.
Another advantage of the present invention is that the composition according to the instant invention simplifies the incorporation of hardly soluble substances in pharmaceutical, cosmetic and nutraceutical applications.
The instant invention thus provides a liposomal composition comprising
Within the context of the present invention, “biosurfactants” are understood as meaning all glycolipids produced by fermentation. The term “biosurfactant” also covers glycolipids that are chemically or enzymatically modified after fermentation, as long as structurally a glycolipid remains.
Raw materials for producing the biosurfactants that can be used are carbohydrates, in particular sugars such as e.g. glucose and/or lipophilic carbon sources such as fats, oils, partial glycerides, fatty acids, fatty alcohols, long-chain saturated or unsaturated hydrocarbons.
Where average values are stated hereinbelow, then, unless stated otherwise, these are number-averaged average values.
Unless stated otherwise, percentages are data in percent by weight.
Wherever measurement values are stated hereinbelow, then, unless stated otherwise, these have been determined at a temperature of 25° C. and a pressure of 1013 mbar.
A preferred composition according to the instant invention is characterized in that the at least one phospholipid is selected from phosphatidylcholines, also known as lecithins and often abbreviated as PC, phosphatidylethanolamines, also known as cephalins and often abbreviated as PE, phosphatidic acid also known as phosphatidates and often abbreviated as PA, phosphatidylserines often abbreviated as PS, phosphoinositides, like for example phosphatidylinositol (often abbreviated as PI), phosphatidylinositol phosphate (often abbreviated as PIP), phosphatidylinositol bisphosphate (often abbreviated as PIP2) and phosphatidylinositol trisphosphate (often abbreviated as PIP3), and phosphosphingolipids, like for example ceramide phosphorylcholines (often abbreviated as SPH), ceramide phosphorylethanolamines (often abbreviated as Cer-PE) and ceramide phosphoryllipids, preferably phosphatidylcholines.
Phospholipids are commonly obtained from biological sources, for examples plants and animals.
Industrial common sources are soya, rapeseed, sunflower, chicken eggs, bovine milk and fish eggs.
Preferably the composition according to the instant invention is characterized in that it comprises as component A) phosphatidylcholines, wherein the phosphatidylcholine is preferably derived from plants, preferably from the group of soya, sunflowers, rapeseed, lupines, pea, and beans, with soya and sunflowers being especially preferred and sunflower the most.
The composition according to the instant invention preferably comprises as component B) at least one biosurfactant selected from rhamnolipids, sophorolipids, glucolipids, cellulose lipids, mannosylerythritol lipids and trehalose lipids, preferably rhamnolipids, sophorolipids, mannosylerythritol lipids and glucolipids, more preferably rhamnolipids, sophorolipids and glucolipids, more preferably rhamnolipids and glucolipids, most preferably rhamnolipids.
The biosurfactants can be produced e.g. as in EP 0 499 434, U.S. Pat. No. 7,985,722, WO 03/006146, JP 60 183032, DE 19648439, DE 19600743, JP 01 304034, CN 1337439, JP 2006 274233, KR 2004033376, JP 2006 083238, JP 2006 070231, WO 03/002700, FR 2740779, DE 2939519, U.S. Pat. No. 7,556,654, FR 2855752, EP 1445302, JP 2008 062179 and JP 2007 181789 or the documents cited therein. Suitable biosurfactants can be acquired e.g. from Soliance, France.
Preferably, the composition according to the instant invention has, as biosurfactant at least one selected from rhamnolipids, in particular mono-, di- or polyrhamnolipids, glucolipids, in particular mono-, di- or polyglucolipids, and sophorolipids, in particular mono-, di- or polysophorolipids, most preferably rhamnolipids.
The term “rhamnolipids” in the context of the present invention preferably is understood to mean particularly compounds of the general formula (I) and salts thereof,
where
If nRL=1, the glycosidic bond between the two rhamnose units is preferably in the α-configuration.
The optically active carbon atoms of the fatty acids are preferably present as R-enantiomers (e.g. (R)-3-{(R)-3-[2-O-(α-L-rhamnopyranosyl)-α-L-rhamnopyranosyl]oxydecanoyl}oxydecanoate).
The term “di-rhamnolipid” in the context of the present invention is understood to mean compounds of the general formula (I) or salts thereof, where nRL=1.
The term “mono-rhamnolipid” in the context of the present invention is understood to mean compounds of the general formula (I) or salts thereof, where nRL=0.
Distinct rhamnolipids are abbreviated according to the following nomenclature: “diRL-CXCY” are understood to mean di-rhamnolipids of the general formula (I), in which one of the residues R1RL and R2RL=(CH2)o—CH3 where o=X-4 and the remaining residue R1 or R2=(CH2)o—CH3 where o=Y-4.
“monoRL-CXCY” are understood to mean mono-rhamnolipids of the general formula (I), in which one of the residues R1RL and R2RL=(CH2)o—CH3 where o=X-4 and the remaining residue R1RL or R2RL=(CH2)o—CH3 where o=Y-4.
The nomenclature used therefore does not distinguish between “CXCY” and “CYCX”.
For rhamnolipids where mRL=O, monoRL-CX or diRL-CX is used accordingly.
If one of the abovementioned indices X and/or Y is provided with “:Z”, this signifies that the respective residue R1RL and/or R2RL is equal to an unbranched, unsubstituted hydrocarbon residue having X-3 or Y-3 carbon atoms having Z double bonds.
Methods for preparing the relevant rhamnolipids are disclosed, for example, in EP2786743 and EP2787065.
Rhamnolipids applicable in the context of the instant invention can also be produced by fermentation of Pseudomonas, especially Pseudomonas aeruginosa, which are preferably non genetically modified cells, a technology already disclosed in the eighties, as documented e.g. in EP0282942 and DE4127908. Rhamnolipids produced in Pseudomonas aeruginosa cells which have been improved for higher rhamnolipid titres by genetical modification can also be used in the context of the instant invention; such cells have for example been disclosed by Lei et aL. in Biotechnol Lett. 2020 June;42(6):997-1002.
Rhamnolipids produced by Pseudomonas aeruginosa are commercially available from Jeneil Biotech Inc., e.g. under the tradename Zonix,from Logos Technologies (technology acquired by Stepan), e.g. under the tradename NatSurFac, from Biotensidion GmbH, e.g. under the tradename Rhapynal, from AGAE technologies, e.g. under the name R90, R95, R95Md, R95Dd, from Locus Bio-Energy Solutions and from Shanghai Yusheng Industry Co. Ltd., e.g. under the tradename Bio-201 Glycolipids.
The present invention provides a composition preferably comprising as biosurfactant rhamnolipids, characterized in that the biosurfactant component B) comprises 51% by weight to 95% by weight, preferably 55% by weight to 80% by weight, particularly preferably 60% by weight to 70% by weight, of diRL-C10C10 and where the percentages by weight refer to the sum of all of the rhamnolipids present.
A preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 0.5% by weight to 15% by weight, preferably 3% by weight to 12% by weight, particularly preferably 5% by weight to 10% by weight, of diRL-C10C12:1, where the percentages by weight refer to the sum of all of the rhamnolipids present.
A further preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 0.5 to 25% by weight, preferably 5% by weight to 15% by weight, particularly preferably 7% by weight to 12% by weight, of diRL-C10C12, where the percentages by weight refer to the sum of all of the rhamnolipids present.
A further preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 0.1% by weight to 25% by weight, preferably 2% by weight to 10% by weight, particularly preferably 4% by weight to 8% by weight, of diRL-C8C10, where the percentages by weight refer to the sum total of all rhamnolipids present.
An even further preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 0.1% by weight to 5% by weight, preferably 0.5% by weight to 3% by weight, particularly preferably 0.5% by weight to 2% by weight, of monoRL-C8C10 and/or, preferably and 0.1% by weight to 5% by weight, preferably 0.5% by weight to 3% by weight, particularly preferably 0.5% by weight to 2% by weight, of monoRL-C10C10, where the percentages by weight refer to the sum of all of the rhamnolipids present.
The present invention provides a composition alternatively preferably comprising as biosurfactant rhamnolipids, characterized in that the biosurfactant component B) comprises 10% by weight to 50% by weight, preferably 20% by weight to 40% by weight, particularly preferably 25% by weight to 35% by weight, of monoRL-C10C10 and where the percentages by weight refer to the sum of all of the rhamnolipids present.
The alternatively preferred composition according to the invention is preferably characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 10% by weight to 30% by weight, preferably 12% by weight to 25% by weight, particularly preferably 15% by weight to 20% by weight, of diRL-C10C10, where the percentages by weight refer to the sum of all of the rhamnolipids present.
The alternatively preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 10% by weight to 30% by weight, preferably 12% by weight to 25% by weight, particularly preferably 15% by weight to 20% by weight, of monoRL-C8C10, where the percentages by weight refer to the sum of all of the rhamnolipids present.
The alternatively preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 3% by weight to 25% by weight, preferably 5% by weight to 20% by weight, particularly preferably 10% by weight to 15% by weight, of monoRL-C10C12:1, where the percentages by weight refer to the sum total of all rhamnolipids present.
The alternatively preferred composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 1% by weight to 15% by weight, preferably 2% by weight to 10% by weight, particularly preferably 3% by weight to 8% by weight, of diRL-C10C12, where the percentages by weight refer to the sum of all of the rhamnolipids present.
In the context of the present invention, the term “sophorolipids” preferably is understood as meaning compounds of the general formulae (Ila) and (Ilb) and salts thereof
Sophorolipids may be used in accordance with the invention in their acid form or their lactone form.
Preferred compositions according to the instant invention comprise a sophorolipid in which the ratio by weight of lactone form to acid form is in the range of 20:80 to 80:20, especially preferably in the ranges of 30:70 to 40:60.
To determine the content of sophorolipids in the acid or lactone form in a formulation, refer to EP1411111B1, page 8, paragraph [0053].
In connection with the present invention, the term “glucolipids” preferably is understood as meaning compounds of the general formula (III) and salts thereof,
The nomenclature used thus does not differentiate between “CXCY” and “CYCX”.
If one of the aforementioned indices X and/or Y is provided with “:Z”, then this means that the respective radical R1GL and/or R2GL=an unbranched, unsubstituted hydrocarbon radical with X-3 or Y-3 carbon atoms having Z double bonds.
Methods for production of glucolipids can be carried out as described in WO2019154970.
It is preferred that a composition according to the instant invention contains component D), the at least one solvent, especially in the case of that component B), the biosurfactant is selected from rhamnolipids.
A preferred composition according to the instant invention is characterized in that the at least one solvent in component D) is selected from alcohols of the group consisting of alkanols and alkenols.
Preferred alkanols and alkenols have preferably 3 to 30 carbon atoms. They can be straight chained like for example propanol, butanol, pentanol, hexanol, heptanol, octanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 1-docosanol, cis-9-Hexadecen-1-ol, cis-9-Octadecen-1-ol, trans-9-Octadecen-1-ol, cis,cis-9,12-Octadecadien-1-ol, 6,9,12-Octadecatrien-1-ol, or branched chained like for example 16-methylheptadecan-1-ol, 3-methyl-1-butanol and octyldodecanol, with straight chained alkanols being preferred.
A preferred composition according to the instant invention is characterized in that the at least one solvent is selected from diols and triols, preferably glycols with preferably 3 to 30 carbon atoms, more preferably from the group consisting of propanediol, butanediol, preferably 1,3-butanediol, pentanediol, preferably 1,2-pentanediol, hexanediol, preferably 1,2-hexanediol, octanediol, preferably 1,2-octanediol, decanediol, preferably 1,2-decanediol, and glycerol, with glycerol being especially preferred.
The compositions according to the instant invention can be used advantageously for the encapsulation and/or stabilisation of active ingredients. Thus, it is preferred in the instant invention, if the composition according to the instant invention comprises
Preferably component E) of the composition according to the instant invention is selected from cosmetic active ingredients.
The cosmetic, pharmaceutical and/or nutraceutical active ingredient comprised in the composition according to the instant invention is preferably contained at least in parts in the bilayer of the liposomes contained in the composition according to the instant invention.
Preferably comprised pharmaceutical and/or nutraceutical active ingredients in this context are selected from glycogen, ceramides, sphingoid bases, sterols, peptides, amino acids, phenols, polyphenols, vitamins, extracts from plants or algae and cosmetic oils, with ceramides, sphingoid bases and sterols being especially preferred.
All ceramides, sphingoid bases, sterols, peptides, polyphenols, vitamins, plant extracts and cosmetic oils, can be comprised in the composition according to the instant invention.
Preferred ceramides comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, ceramide NP, ceramide AP, ceramide EOP, ceramide NDS, ceramide ADS, ceramide EODS, ceramide NS, ceramide AS, ceramide EOS, ceramide NH, ceramide AH and ceramide EOH, preferably selected from the group comprising, preferably consisting of, ceramide NP, ceramide AP, ceramide NS, ceramide EOP and ceramide EOS.
The ceramide nomenclature is commonly used and is described in more detail in Farwick et al.
Developments in Ceramide Identification, Synthesis, Function and Nomenclature, Cosmet Toil 2009; 124: 63-72.
Preferred sphingoid bases comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, sphingosine, sphinganine, 6-hydroxysphingosine and phytosphingosine.
Preferred sterols comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, cholesterol, 7-dehydrocholesterol, potassium cholesterol sulfate, cholesteryl succinate, 25-hydroxy-7-dehydrocholesterol, ergosterol, fucosterol, hopanoids, hydroxysteroid, phytosterols like for example campesterol, sitosterol,and stigmasterol, steroids and zoosterols, with cholesterol being especially preferred.
Preferred peptides comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, palmitoyl hexapeptide-12, palmitoyl oligopeptide, palmitoyl pentapeptide-3, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, collagen, elastin, epidermal growth factor (EGF), epitalon and fibronectin.
Preferred amino acids comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, proteinogenic amino acids, preferably alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine and tryptophan.
Preferred phenols and polyphenols comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, resveratrol, quercetin, rutin, ellagic acid, apigenin, phloretin, caftaric acid, caffeic acid phenylethyl ester, pterostilbene, luteolin, fisetin, honokiol, ferulic acid and sinapic acid.
Preferred vitamins comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, coenzyme q10 (ubiquinone), biotin, vitamin A, retin-A, retinoids, retinol, retinaldehyde, retinol palmitate, retinyl ascorbate, retinyl palmitate, retinyl retinoate, vitamin D, cholecalciferol, ergocalciferol, vitamin E, preferably alpha-, beta-, gamma-, and delta-tocopherol, tocopherol, tocopherol acetate, tocopheryl acetate, tocopheryl lineolate, tocopheryl linoleate, tocopheryl linoleate/oleate, tocopheryl nicotinate, tocopheryl succinate, tocotrienols, vitamin K and vitamin C, preferably ascorbyl palmitate.
Preferred extracts from plants or algae comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, aloe (especially vera) extract, aesculus hippocastanum extract, Calendula officinalis flower extract, centella asiatica extract, bakuchiol, ascophyllum nodosum extract, acemannan, coleus barbatus extract, cranberry seed extract, Ginkgo biloba leaf extract, ginseng extract, grapefruit peel extract, green tea extract, Hordeum vulgare extract, horse chestnut extract, Oryza sativa (rice) extract, pectin, Polygonum cuspidatum root extract, pomegranate extract, spirulina extract, squalene, st. john's wort extract, willow bark extract, capsaicin, capsicum extracts, Glycyrrhiza glabra extract, madecassoside, Rosmarinus officinalis extract, ruscogenine, carotinoids, preferably astaxanthin, ß-carotin, canthaxanthin, capsanthin, capsorubin, cryptoxanthin, lutein, luteoxanthin, lycopin and zeaxanthin, chamomilla recutita (matricaria) flower extract, sesamin, pyrus malus fruit extract, baicalein, puerarin, phlorizin, 1,4-dicaffeoylquinic acid, myricetin-3-o-p-rhamnoside, dihydromyricetin, diosmetin, 6-gingerol and mangnolol.
Preferred cosmetic oils comprised in the composition according to the instant invention are selected from the group comprising, preferably consisting of, argan oil, almond oil, blackcurrant oil, chia oil, Cannabis sativa I. oil, avocado oil (persea gratissima), caprylic/capric triglycerides, cotton seed oil, hemp oil, canola oil, marula oil, peach kernel oil, perilla oil, pomegranate seed oil, pumpkin seed oil, sea buckthorn oil, coconut oil, coconut oil-derived fatty acids, glycine soja oil, Helianthus annuus seed oil, jojoba oil, macadamia nut oil, persea gratissima oil, Triticum vulgare (wheat) germ oil, grape seed oil, MCT oil, grapefruit oil, ginger oil, butyrospermum parkii (shea) butter, Camellia sinensis seed oil, cocoa butter, coconut oil and evening primrose oil.
It is an advantage of the instant invention, that a multitude of different cosmetic, pharmaceutical and/or nutraceutical active ingredients can be comprised in the composition according to the instant invention.
Preferably the composition according to the instant invention comprises as component E) at least one ceramide and cholesterol, more preferably at least one ceramide, at least one sphingoid base and cholesterol.
The weight ratio of the sum of all ceramides and as may be the case all sphingoid bases comprised in the composition according to the instant invention to cholesterol in this context is preferably in the range of from 1000:1 to 1:100, more preferably from 100:1 to 1:10 and most preferably from 10:1 to 1:1, respectively.
The compositions according to the instant invention are liposomal compositions, thus they comprise liposomes. Preferably the liposomes comprised in composition according to the instant invention have a mean particle size of 15 nm to 800 nm, preferably of 50 nm to 500 nm, more preferably of 60 nm to 350 nm and even more preferably of 80 nm to 240 nm.
Photon correlation spectroscopy is employed in order to determine the mean particle size. The measurement is performed using a Zetasizer Nano ZS90, Malvern Instruments Ltd., UK, according to the manufacturer's instruction. The Z-average is the intensity weighted mean hydrodynamic size of the ensemble collection of particles measured by dynamic light scattering (DLS). The Z-average is derived from a Cumulants analysis of the measured correlation curve, wherein a single particle size is assumed and a single exponential fit is applied to the autocorrelation function (see Zetasizer Nano ZS90 User Manual MAN0485-1-1 9 Jun. 2017).
A preferred composition according to the instant invention is characterized in that it comprises
This resembles a concentrated stock of a liposomal composition.
In case component E) is comprised, this preferred composition according to the instant invention is very well suited as a storage vehicle for cosmetic, pharmaceutical and/or nutraceutical active ingredients.
These compositions allow for easy handling of the actives and also for formulating end customer formulations with ease.
Thus, the present invention further relates to formulations, especially cosmetic, pharmaceutical, dermatological or nutraceutical formulations, most preferably cosmetic formulations, comprising the composition according to the instant invention.
The formulations according to the invention can further comprise at least one additional component selected from the group of
Substances which can be used as exemplary representatives of the individual groups are known to those skilled in the art and can be found for example in German application DE 102008001788.4.
This patent application is hereby incorporated as reference and thus forms part of the disclosure.
As regards further optional components and the amounts used of these components, reference is made expressly to the relevant handbooks known to those skilled in the art, for example K.
Schrader, “Grundlagen und Rezepturen der Kosmetika [Cosmetics—fundamentals and formulations]”, 2nd edition, pages 329 to 341, Huthig Buch Verlag Heidelberg.
The amounts of the particular additives are determined by the intended use.
Typical boundary formulations for the respective applications are known prior art and are contained for example in the brochures of the manufacturers of the particular base and active ingredients.
These existing formulations can generally be adopted unchanged. However, if required, for adjustment and optimization, the desired modifications can be undertaken by simple tests without complication.
Preferred formulations according to the instant invention are characterized in that they comprise
The components A) to E) are the same as comprised in the composition according to the instant invention. D) and E) can be comprised in higher ratios compared to the other components than in the composition according to the instant invention. For example, it is common to add further solvent (component D)) or cosmetic oils (component E)) to end customer formulations.
A particularly preferred composition according to the invention and also a preferred formulation according to the instant invention is characterized in that it has a pH in the range of 4.0 to 8.0, preferably 4.5 to 7.5 particularly preferably 4.5 to 6.5.
The “pH” in connection with the present invention is defined as the value which is measured for the relevant composition at 22° C. after stirring for five minutes using a pH electrode calibrated in accordance with ISO 4316 (1977).
The present invention further relates to a process for encapsulating at least one cosmetic, pharmaceutical and/or nutraceutical active ingredient comprising the steps
Preferably the same preferred components A) to E) are used in the same preferred embodiments in the process of the instant invention as described above for the composition according to the instant invention.
The combining of the components A) to E) in process step III) of the process of the instant invention is preferably done while stirring, preferably while homogenizing by stirring.
Preferably an additional homogenization is carried out. This comprises for example a high shear rate homogenization with a stirrer speed of from 3,000 rpm to 25,000 rpm and typically at 5,000 rpm to 20,000 rpm and/or high pressure homogenization, preferably at from 100 bar to 1000 bar and typically at 500 bar to 700 bar.
The present invention further relates to the use of at least on composition according to the instant invention for encapsulation of at least one cosmetic, pharmaceutical and/or nutraceutical active ingredient. The active ingredient to be encapsulated is preferably those of component E) of the composition according to the instant invention.
The examples adduced hereinafter describe the present invention by way of example, without any intention that the invention, the scope of application of which is apparent from the entirety of the description and the claims, be restricted to the embodiments specified in the examples.
Rhamnolipids were prepared as described in EP3023431.
The sophorolipid used is a sophorolipid REWOFERM SL ONE from Evonik, which has a lactone to acid ratio of 40:60.
Glucolipids were produced according to example 2 of WO2019154970 via fermentation.
In order to produce liposomal composition according to example 1, the lecithin was stirred together with the glycerol and rhamnolipid at a temperature of 85° C. for 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) were checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process was terminated after a mean particle size with a diameter of about 190 nm and PDI<0.2.
In order to produce liposomal composition according to example 2, the lecithin was stirred together with the glycerol and rhamnolipid at a temperature of 85° C. for 60 minutes. The active ingredients were added and stirring was conducted for additional 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) were checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process was terminated after a mean particle size with a diameter of about 160 nm and PDI<0.2.
In order to produce liposomal composition according to example 3, the lecithin is stirred together with the glycerol, 1,2-pentanediol and 1,3-butanediol and rhamnolipid at a temperature of 85° C. for 60 minutes. The active ingredient is added and stirring is conducted for additional 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and a PDI of 0.2.
In order to produce liposomal composition according to example 4, the lecithin was stirred together 30 with the glycerol and polysorbate-80 at a temperature of 85° C. for 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) were checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process was terminated after a mean particle size with a diameter of about 106 nm and PDI<0.2.
In order to produce liposomal composition according to example 5, the lecithin was stirred together with the glycerol and polysorbate-80 at a temperature of 85° C. for 60 minutes. The active ingredients were added and stirring was conducted for additional 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) were checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process was terminated after a mean particle size with a diameter of about 160 nm and PDI<0.3.
In order to produce liposomal composition according to example 5b, the lecithin was stirred together with the glycerol at a temperature of 85° C. for 60 minutes. The active ingredient was added and stirring was conducted for additional 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
No stable liposomal compositions could be prepared with the above components, no particle size or PDI could thus be determined.
In order to produce liposomal composition according to example 11, the lecithin was stirred together with the glycerol and rhamnolipid at a temperature of 85° C. for 60 minutes. The active ingredient was added and stirring was conducted for additional 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) were checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process was terminated after a mean particle size with a diameter of about 218 nm and PDI<0.3.
In order to produce liposomal composition according to example 12, the lecithin was stirred together with the glycerol and polysorbate-80 at a temperature of 85° C. for 60 minutes. The active ingredient was added and stirring was conducted for additional 60 minutes.
The water, which had also been pre-heated to 85° C., was incorporated into the composition above while homogenizing for another 4 minutes. The preservative Optiphen BD was finally added with homogenizing for another 1 minute.
The final liposomal composition had the following content; 100 grams in total were prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) were checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process was terminated after a mean particle size with a diameter of about 200 nm and a PDI 0.5.
In comparison to example 6 it proven by the high PDI, that the liposomal composition of example 7 is not properly stable.
The compositions of examples 2, 3 and 5 were stored at different temperatures and examined for occurrence of crystals at different time point: Crystallization is observable two weeks after storage at room temperature and 4000 for example 5, whereas example 2 and 3 show no crystallisation at all.
The following liposomal compositions are prepared according to example H2 of EP1 138311:
Separation of salicylic acid 2-ethylhexyl ester is observable 28 weeks after storage at room temperature and 12 weeks after storage at 4000 for preparation V1 and V2, whereas 8Rr, 8Rs, 8Rg, 8RR, 8RS, 8RG show no separation at all.
The following liposomal compositions are prepared according to example H2 of EPi1138311 without Squalane:
Separation of salicylic acid 2-ethylhexyl ester is observable 28 weeks after storage at room temperature and 9 weeks after storage at 40° C. for preparation V3, whereas 9Rr, 9Rs and 9Rg show no separation at all.
In order to produce liposomal composition according to example 9, the lecithin is stirred together with the glycerol and glucolipid at a temperature of 85° C. for 60 minutes. The active ingredients are added and stirring is conducted for additional 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared: Glucolipids were produced as described in the examples of WO2019154970.
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
In order to produce liposomal composition according to example 10, the lecithin is stirred together with the glycerol and sophorolipid at a temperature of 85° C. for 60 minutes. The active ingredients are added and stirring is conducted for additional 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared: The sophorolipid used is a sophorolipid “SL 18” from Ecover, which has an acid to lactone ratio of 70:30.
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
The final liposomal composition has the following content; 100 grams in total are prepared:
In order to produce liposomal composition according to example 9, the lecithin is stirred together with the glycerol and PEG-6 Caprylic/Capric Glycerides at a temperature of 85° C. for 60 minutes. The active ingredients are added and stirring was conducted for additional 60 minutes. The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with stirring for another 1 minute.
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
The liposomal compositions of example 9 to 11 are deep frozen in a −20° C. refrigerator for 3 hours and thawed in a 30° C. water bath. This procedure is repeated four times and the compositions are subsequently analyzed for crystal occurrence.
Crystallization is observed after repeated freeze/thaw cycles in example 11, whereas example 9 and 10 show no re-crystallisation at all.
The physical stability of the formulations and the resulting liposome stability is determined by pH value, particle size and polydispersity index measurements using a pH meter and photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction.
Formulations are stored at 4° C., room temperature and 40° C. and measured over the course of 48 weeks.
Strongly affected stability of the liposomes is given, when the pH shifts more than +/−2 units, liposome particle size increases by more than 400 nm and/or the polydispersity index is above 0.4.
In order to produce liposomal composition according to example 14, the lecithin is stirred together with the glycerol and rhamnolipid at a temperature of 85° C. for 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
In order to produce liposomal composition according to example 15, the lecithin is stirred together with the glycerol and glucolipid at a temperature of 85° C. for 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
In order to produce liposomal composition according to example 16, the lecithin is stirred together with the glycerol and sophorolipid at a temperature of 85° C. for 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
In order to produce liposomal composition according to example 17, the lecithin is stirred together with the glycerol and rhamnolipid at a temperature of 85° C. for 60 minutes. The active ingredient is added and stirring is conducted for additional 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
In order to produce liposomal composition according to example 18, the lecithin is stirred together with the glycerol and glucolipid at a temperature of 85° C. for 60 minutes. The active ingredient is added and stirring is conducted for additional 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
In order to produce liposomal composition according to example 19, the lecithin is stirred together with the glycerol and sophorolipid at a temperature of 85° C. for 60 minutes. The active ingredient is added and stirring is conducted for additional 60 minutes.
The water, which has also been pre-heated to 85° C., is incorporated into the composition above while homogenizing for 4 minutes. The preservative Optiphen BD is finally added with homogenizing for another 1 minute.
The final liposomal composition has the following content; 100 grams in total are prepared:
The particle size of the lipid vesicles produced by this process and the polydispersity index (PDI) are checked using photon correlation spectroscopy (PCS, Zetasizer Nano ZS90, Malvern Instruments Ltd., UK) according to the manufacturer's instruction; the production process is terminated after a mean particle size with a diameter of about 200 nm and PDI<0.2.
2, 3, 6, 9, 10, 17, 18 or 19; thus, for each formulation listed 8 formulations are prepared. “example X”=examples 2, 3, 6, 9, 10, 17, 18 or 19.
| Number | Date | Country | Kind |
|---|---|---|---|
| 22158501.1 | Feb 2022 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2023/054171 | 2/20/2023 | WO |
